The development of targeted new agents to improve the outcome for children with leukemia

Francisco BautistaDepartment of Pediatric Oncology, Hematology and Stem Cell Transplantation, Hospital Niño Jesús, Madrid, SpainView further author information

Jasper Van der LugtDepartment of Pediatric Oncology/Hematology, Erasmus-MC Sophia Children’s Hospital, Rotterdam, The NetherlandsView further author information

Pamela R. KearnsCancer Research UK Clinical Trials Unit, School of Cancer Sciences, University of Birmingham, Birmingham, UKView further author information

Francis J. MussaiCancer Research UK Clinical Trials Unit, School of Cancer Sciences, University of Birmingham, Birmingham, UKView further author information

C. Michel ZwaanDepartment of Pediatric Oncology/Hematology, Erasmus-MC Sophia Children’s Hospital, Rotterdam, The NetherlandsView further author information

Lucas MorenoDepartment of Pediatric Oncology, Hematology and Stem Cell Transplantation, Hospital Niño Jesús, Madrid, SpainCorrespondence[email protected]
View further author information

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (7)

Jing Liu, Li Zhang, Ling Guo, Yan Zeng, Qulian Guo, Chunmei Yang, Jian Shu, Wenjun Liu & Lu Yang. (2022) Novel bioactive hybrid Celecoxib-HDAC Inhibitor, induces apoptosis in human acute lymphoblastic leukemia cells. Bioorganic & Medicinal Chemistry 75, pages 117085.
Crossref

Manon Queudeville & Martin Ebinger. (2021) Blinatumomab in Pediatric Acute Lymphoblastic Leukemia—From Salvage to First Line Therapy (A Systematic Review). Journal of Clinical Medicine 10:12, pages 2544.
Crossref

Olivia C. Finney, Hannah Brakke, Stephanie Rawlings-Rhea, Roxana Hicks, Danielle Doolittle, Marisa Lopez, Ben Futrell, Rimas J. Orentas, Daniel Li, Rebecca Gardner & Michael C. Jensen. (2019) CD19 CAR T cell product and disease attributes predict leukemia remission durability. Journal of Clinical Investigation 129:5, pages 2123-2132.
Crossref

Carmela De Santo, Sarah Booth, Ashley Vardon, Antony Cousins, Vanessa Tubb, Tracey Perry, Boris Noyvert, Andrew Beggs, Margaret Ng, Christina Halsey, Pamela Kearns, Paul Cheng & Francis Mussai. (2017) The arginine metabolome in acute lymphoblastic leukemia can be targeted by the pegylated‐recombinant arginase I BCT‐100. International Journal of Cancer 142:7, pages 1490-1502.
Crossref

Jing Su, Geyi Liu, Yumei Lian, Zul Kamal, Xiao Que, Yujiao Qiu & Mingfeng Qiu. (2018) Preparation and characterization of erythrocyte membrane cloaked PLGA/arsenic trioxide nanoparticles and evaluation of their in vitro anti-tumor effect . RSC Advances 8:36, pages 20068-20076.
Crossref

Ashley Vardon, Madhumita Dandapani, Daryl Cheng, Paul Cheng, Carmela De Santo & Francis Mussai. (2017) Arginine auxotrophic gene signature in paediatric sarcomas and brain tumours provides a viable target for arginine depletion therapies. Oncotarget 8:38, pages 63506-63517.
Crossref

Andrew D J Pearson, Stefan M Pfister, Andre Baruchel, Jean-Pierre Bourquin, Michela Casanova, Louis Chesler, François Doz, Angelika Eggert, Birgit Geoerger, David T W Jones, Pamela R Kearns, Jan J Molenaar, Bruce Morland, Gudrun Schleiermacher, Johannes H Schulte, Josef Vormoor, Lynley V Marshall, C Michel Zwaan & Gilles Vassal. (2017) From class waivers to precision medicine in paediatric oncology. The Lancet Oncology 18:7, pages e394-e404.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

The development of targeted new agents to improve the outcome for children with leukemia

Articles from other publishers (7)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The development of targeted new agents to improve the outcome for children with leukemia

Citations (7)

Articles from other publishers (7)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date